Adinatha
-
Posts
495 -
Joined
-
Last visited
Content Type
Gallery
Calendar
Forums
Everything posted by Adinatha
-
Psilocibina em cuidados paliativos http://www.sciencedaily.com/releases/2010/09/100906202905.htm In the first human study of its kind to be published in more than 35 years, researchers found psilocybin, an hallucinogen which occurs naturally in "magic mushrooms," can safely improve the moods of patients with advanced-stage cancer and anxiety, according to an article published online September 6 in the Archives of General Psychiatry. Patients enrolled in the study at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) demonstrated improvement of mood and reduction of anxiety up to six months after undergoing treatment, with significance reached at the six-month point on the "Beck Depression Inventory" and at one and three months on the "State-Trait Anxiety Inventory." A third screening tool, the "Profile of Mood States," identified mood improvement after treatment that approached but did not reach significance. "We are working with a patient population that often does not respond well to conventional treatments," said Charles S. Grob, MD, an LA BioMed principal investigator who led the research team. "Following their treatments with psilocybin, the patients and their families reported benefit from the use of this hallucinogen in reducing their anxiety. This study shows psilocybin can be administered safely, and that further investigation of hallucinogens should be pursued to determine their potential benefits." Researchers conducted extensive investigations of psychedelic drugs in the 1950s and 1960s and found promising improvements in mood and anxiety, as well as a diminished need for narcotic pain medication among advanced-stage cancer patients. The research was abandoned in the early 1970s in the wake of widespread recreational usage that led to stiff federal laws regulating hallucinogens. "Political and cultural pressures forced an end to these studies in the 1970s," said Dr. Grob. "We were able to revive this research under strict federal supervision and demonstrate that this is a field of study with great promise for alleviating anxiety and other psychiatric symptoms." The LA BioMed study is the first research publication in several decades to examine the hallucinogen treatment model with advanced-cancer anxiety. Twelve volunteers, ages 36 to 58, with advanced-stage cancer and anxiety were given a moderate dose of 0.2 mg/kg of psilocybin and, on a separate occasion, a placebo. Neither the volunteers nor the researchers monitoring them knew whether they'd been given a placebo or psilocybin. The two experimental sessions took place several weeks apart in a hospital clinical research unit at Harbor-UCLA Medical Center, where Dr. Grob is a professor of psychiatry. The research volunteers were monitored for the six hours following their dose. The volunteers were encouraged to lie in bed, wear eye shades and listen to music during the first few hours after ingesting the medication or the placebo. They were interviewed after the six-hour session and over the next six months to assess the outcome of the treatment. This study was funded by the Heffter Research Institute, the Betsy Gordon Foundation and the Nathan Cummings Foundation (with the support and encouragement of James R. Cummings). Infrastructural support for this study was provided via grant M01-RR00425 from the National Institutes of Health for the General Clinical Research Unit at LA BioMed.
-
Contribui, mas não é só isso Children of Bodom \m/
-
Acidfreak, compreendo e também gosto de ver, mas o trance não é só isso É como no metal... lá porque não vestes preto não és "do metal"?
-
LOL?
-
Isso é que eu duvido muito. Era, era Então, há umas semanas atrás houve uma possibilidade de um caso de febre do Nilo em Lisboa, que mais tarde se confirmou, mas não passou daí, e foi abertura...
-
Seria, asseguro-te. Ninguém ligou a irresponsabilidade individual ou o caso de sarampo ao Boom, se fosse detectado num qualquer centro de saúde teria sido notícia na mesma Por isso é que eu disse "supostamente" erradicada. É uma infectocontagiosa, por isso podem surgir casos muito pontuais.
-
-.-' Sinceramente... Meus, vão para jornalistas, já que têm tanto mérito em escrutinizar o que é notícia do que não é.
-
A importância é que o sarampo estava, supostamente, erradicado na Europa, e é uma doença, "perigosa em adultos" como podes lá ler. Não é uma constipação.
-
A única coisa que tem a ver com o festival, e que refere na notícia, é o facto de haver facilidade de contágio devido à multiculturalidade, gente que vem de países onde as taxas de vacinação são menores, etc. Não juntei o caso de sarampo ao festival, apenas divulguei uma notícia SOBRE o mesmo. -.-'
-
"O paciente não estava vacinado contra a doença, “por opção familiar”, tal como o irmão adolescente com quem tinha contactado diretamente e a quem tinha sido diagnosticado sarampo, 15 dias antes, no Reino Unido, explicou." É assim que as epidemias erradicadas reaparecem, mas isso já são contas de outro rosário...
-
http://www.ionline.pt/conteudo/76015-sarampo-no-boom-festival-nao-representa-risco Ora aí está a prova que foi um festival com muita pinta!
-
Grande line up... Pode ser que seja desta
-
Oh miguel, tu tiraste o dia para vir trollar, mesmo...
-
Meu, tu vais ao Boom para ver mulheres? :facepalm da minha vida!:
-
"O Átomo Assombrado "
-
É passar do http://www.youtube.com/watch?v=v5-7pce5OOQ Para a
-
http://www.newsdaily.com/stories/tre67h0s6-us-depression-psychedelics/ LONDON, Aug. 18, 2010 (Reuters) — Mind-altering drugs like LSD, ketamine or magic mushrooms could be combined with psychotherapy to treat Research into the effects of psychedelics, used in the past in psychiatry, has been restricted in recent decades because of the negative connotations of drugs, but the scientists said more studies into their clinical potential were now justified. The researchers said recent brain imaging studies show that psychedelics such as lysergic acid diethylamide (LSD), ketamine and psilocybin -- the psychoactive component in recreational drugs known as magic mushrooms -- act on the brain in ways that could help reduce symptoms of various psychiatric disorders. The drugs could be used as a kind of catalyst, the scientists said, helping patients to alter their perception of problems or pain levels and then work with behavioral therapists or psychotherapists to tackle them in new ways. "Psychedelics can give patients a new perspective -- particularly when things like suppressed memories come up -- and then they can work with that experience," said Franz Vollenweider of the Neuropsychopharmacology and brain imaging unit at Zurich's University Hospital of Psychiatry, who published a paper on the issue in Nature Neuroscience journal. Depending on the type of person taking the drug, the dose and the situation, psychedelics can have a wide range of effects, experts say, from feelings of boundlessness and bliss at one end of the spectrum to anxiety-inducing feelings of loss of control and panic at the other. LOW DOSES Vollenweider and his colleague Michael Kometer, who also worked on the paper, said evidence from previous studies suggests such drugs might help ease mental health problems by acting on the brain circuits and neurotransmitter systems that are known to be altered in people with depression and anxiety. But if doctors were to use them to treat psychiatric patients in future, it would be important to keep doses of the drugs low, and ensure they were given over a relatively short time period in combination with therapy sessions, they said. "The idea is that it would be very limited, maybe several sessions over a few months, not a long-term thing like other types of medication," Vollenweider said in a phone interview. A small study published by U.S. scientists this month found that an infusion of ketamine -- an anaesthetic used legally in both human and veterinary medicine, but also abused by people who use it recreationally -- can lift the mood within minutes in patients with severe bipolar depression. Mental illnesses such as depression are a growing health problem around the world and Vollenweider and Kometer said many patients with severe or chronic psychiatric problems fail to respond to medicines like the widely-prescribed selective serotonin reuptake inhibitors, or SSRIs, like Prozac or Paxil. "These are serious, debilitating, life-shortening illnesses, and as the currently available treatments have high failure rates, psychedelics might offer alternative treatment strategies that could improve the well-being of patients and the associated economic burden on patients and society," they wrote.
-
Pois... Não vi essa cena, devia estar a curti-la algures... xD
-
Excelente artigo, obrigada Parece coisa feia.
-
Li na net uma notícia em que o fulano que sequestrou aquele autocarro nas Filipinas teria, em 2008, obrigado um estudante a engolir shabu. Ora, o fulano foi indiciado por crimes ligados à droga, e pelo que percebi, shabu é uma droga amplamente usada nas Filipinas. Alguém me explica mais sobre isso, o que é, o que faz?
-
Estou com o AlienX e com o Sage. Quem foi ou ainda lá está ou já veio e está a deixar a cabeça aterrar xD
-
Ai, quero :x Afundaaaaa
-
Amigo, tu larga a droga! Em que é que te foste meter.... Não largo! É minhaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa!!!! Xiiiii... Tenho ainda pra aí uns 3/4 baralhos disso... Belos tempos... hoje em dia já nng joga às cartas... Já é tudo virtual... Eu jogo!!